2021
Percutaneous electrical nerve field stimulation to reduce clinical opiate withdrawal: a case series
Buono F, Pickering R, Berlepsch R, Halligan S. Percutaneous electrical nerve field stimulation to reduce clinical opiate withdrawal: a case series. Journal Of Substance Use 2021, 27: 501-504. DOI: 10.1080/14659891.2021.1961894.Peer-Reviewed Original ResearchClinical Opiate Withdrawal ScaleMedication-Assisted TreatmentWithdrawal symptomsCase seriesPercutaneous electrical nerve field stimulationOpiate withdrawal symptomsOpioid withdrawal symptomsRetrospective case seriesOpiate use disorderOpiate Withdrawal ScaleCOWS scoresAdult patientsClinical reviewProspective studyClinician interviewsOpiate withdrawalField stimulationWithdrawal ScaleSide effectsUse disordersDay 1Practical nursesDay 5Negative symptomsSymptoms
2015
Early Life Stress as a Risk Factor for Substance use Disorders: Clinical and Neurobiological Substrates
Varghese SP, Montalvo-Ortiz JL, Csernansky JG, Eiger RI, Herrold AA, Koola MM, Dong H. Early Life Stress as a Risk Factor for Substance use Disorders: Clinical and Neurobiological Substrates. Indian Journal Of Psychological Medicine 2015, 37: 36-41. PMID: 25722510, PMCID: PMC4341308, DOI: 10.4103/0253-7176.150816.Peer-Reviewed Original ResearchEarly life stressWithdrawal symptomsMorphine administrationMorphine sensitizationWT miceCRF-OEOpiate withdrawal symptomsDoses of morphineCRF-OE miceEffects of ELSLife stressWild-type miceSubstance use disordersCRF miceRisk factorsImmunohistochemistry studiesNucleus accumbensType miceImmunohistochemistry analysisUse disordersMorphineBehavioral trialsSymptomsMiceElevated levels
2011
Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients
McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug And Alcohol Dependence 2011, 118: 326-334. PMID: 21596492, PMCID: PMC3272858, DOI: 10.1016/j.drugalcdep.2011.04.013.Peer-Reviewed Original ResearchConceptsBuprenorphine plasma concentrationsWithdrawal symptomsOpiate withdrawalPlasma concentrationsBuprenorphine-maintained patientsBuprenorphine-maintained subjectsDays of rifampinOpioid partial agonistBuprenorphine/naloxoneFirst-line treatmentOpiate withdrawal symptomsSignificant adverse eventsActive metabolite concentrationsOpioid-dependent individualsPlasma buprenorphine concentrationsBuprenorphine pharmacokineticsStable dosesAdverse eventsBuprenorphine doseBuprenorphine therapyAntituberculosis medicationPharmacodynamic interactionsRifampin administrationOpioid dependenceLine treatment
2006
Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphine
2003
The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients
McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients. Clinical Infectious Diseases 2003, 37: 476-482. PMID: 12905130, DOI: 10.1086/376907.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirMethadone metabolismSubstance abuse pharmacotherapyOpiate withdrawal symptomsInjection drug usersConcentration-time curveMethadone areaMethadone dosesHIV diseaseMethadone concentrationsOral clearancePharmacodynamic interactionsWithdrawal symptomsOpiate withdrawalClinical monitoringDrug usersSame dosageRitonavirPotent inducerPatientsMethadoneProtease inhibitorsSignificant reductionR formulationTreatment
2001
Neurotrophin-3 modulates noradrenergic neuron function and opiate withdrawal
Akbarian S, Bates B, Liu R, Skirboll S, Pejchal T, Coppola V, Sun L, Fan G, Kucera J, Wilson M, Tessarollo L, Kosofsky B, Taylor J, Bothwell M, Nestler E, Aghajanian G, Jaenisch R. Neurotrophin-3 modulates noradrenergic neuron function and opiate withdrawal. Molecular Psychiatry 2001, 6: 593-604. PMID: 11526474, DOI: 10.1038/sj.mp.4000897.Peer-Reviewed Original ResearchMeSH KeywordsAgingAnimalsAvoidance LearningBrainColforsinCyclic AMPElectric StimulationEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Gene Expression Regulation, EnzymologicIn Vitro TechniquesIntermediate Filament ProteinsLocus CoeruleusMiceMice, KnockoutMice, TransgenicMorphineMorphine DependenceNerve Tissue ProteinsNestinNeuronsNeurotrophin 3Signal TransductionSubstance Withdrawal SyndromeTyrosine 3-MonooxygenaseConceptsNoradrenergic neuronsNeurotrophin-3NT-3Opiate withdrawalNoradrenergic signalingOpiate withdrawal symptomsChronic morphine exposureNT-3 expressionNon-catecholaminergic neuronsLoss of neuronsDorsal medullaMorphine exposureWithdrawal symptomsAfferent sourcesTyrosine hydroxylaseAdult brainSomatic symptomsNeuron functionVentral forebrainConditional ablationReduced upregulationNeuronsAltered cAMPSymptomsWithdrawal
1999
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
Altice F, Friedland G, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999, 13: 957-962. PMID: 10371177, DOI: 10.1097/00002030-199905280-00012.Peer-Reviewed Original ResearchConceptsPharmacokinetic interactionsOpiate withdrawalMethadone levelsWithdrawal symptomsChronic methadone maintenance therapyNon-nucleoside reverse transcriptase inhibitorSubstance abuseInitiation of therapyMethadone maintenance therapyOpiate withdrawal symptomsRetrospective chart reviewSignificant pharmacokinetic interactionsInjection drug usersReverse transcriptase inhibitorHIV therapeutic agentsAntiretroviral therapyMaintenance therapyMethadone doseChart reviewHIV diseaseHIV infectionIncreased doseTranscriptase inhibitorTherapeutic benefitPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply